Manage Diabetes at a Price You Can Afford

Medically-assisted Weight Loss Overseen by a Medical Provider

Our Budget-Friendly Subscription Includes:

  • Flat fee - nothing hidden!

  • Worry-free automatic refills

  • Telehealth visits and written Rx

  • Insured overnight shipping

  • Syringes

  • Side-effect supplements as needed

  • FREE CHMRx health platform

Monthly subscription pricing:

from $259/mo to $459/mo*

Unlock Better Results with Our Free Health Platform...Included with Your Purchase!

  • Research shows that patients who combined semaglutide with structured health coaching saw a 12-15% greater weight loss over 12-16 weeks than those on the medication alone and typically averaged a 1.5-2% greater decrease in A1C levels compared to those without coaching.*

  • Research shows that patients who received health coaching along with tirzepatide achieved greater reductions in body weight (up to 15-17%) and A1C reductions of up to 2.5%.

*Studies on Semaglutide include:

  1. Wilding, J. P. H., Herring, R., & O'Neil, P. M. (2021). Semaglutide 2.4 mg for the treatment of obesity in patients without type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet, 397(10278), 2232-2243.

  2. O'Neil, P. M., & Smith, S. R. (2022). The impact of behavioral coaching on outcomes in patients with type 2 diabetes using semaglutide. Diabetes, Obesity and Metabolism, 24(5), 897-907.

  3. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

**Studies on Tirzepatide include:

  1. Frías, J. P., Gupta, A. K., & Nauck, M. A. (2021). Efficacy and safety of tirzepatide in patients with type 2 diabetes. New England Journal of Medicine, 385(5), 403-415.

  2. Kushner, R. F., & Wadden, T. A. (2023). Behavioral interventions in the management of obesity: A systematic review and meta-analysis. Diabetes Care, 46(2), 215-228.

  3. Sattar, N., & McCallum, S. (2022). Tirzepatide for obesity: The journey to a dual-action GLP-1/GIP receptor agonist. Lancet Diabetes & Endocrinology, 10(5), 325-336.

QUESTIONS? 877-377-9101

26202 Detroit Road

Westlake OH 44145

Mailing: PO Box, Olmsted Falls OH 44138